Twenty-eight mild , atopic asthmatic subjects were recruited for a double-blind , randomized , placebo-controlled , parallel-group trial ( ClinicalTrials.gov identifier NCT@ ) to compare blockade of OX@L using a humanized anti-OX@L MAb to placebo-administered intravenously in @ doses over @ months .